Bahrain
Tuberculosis profile
Population  2012 1.3 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) <0.01 (<0.01–<0.01) 0.34 (0.28–0.41)
Mortality (HIV+TB only) <0.01 (<0.01–0.014) 0.25 (0–1.1)
Prevalence  (includes HIV+TB) 0.38 (0.18–0.65) 29 (14–49)
Incidence  (includes HIV+TB) 0.26 (0.23–0.29) 20 (17–22)
Incidence (HIV+TB only) 0.012 (<0.01–0.025) 0.89 (0.25–1.9)
Case detection, all forms (%) 87 (77–99)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 101 (45) Relapse 0  
Smear-negative 47 (21) Treatment after failure 0  
Smear-unknown / not done 0 (0) Treatment after default 0  
Extrapulmonary 77 (34) Other 0  
Other 0 (0)      
Total new 225   Total retreatment 0  
           
Other (history unknown) 0        
Total new and relapse 225   Total cases notified 225  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 2.7 1.1 1.5
Age < 15 1 0 2
Laboratories 2012
Smear (per 100 000 population) 1.4
Culture (per 5 million population) 7.6
Drug susceptibility testing (per 5 million population) 3.8
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 34   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 95  
Retreatment    
TB/HIV 2012 Number (%)
TB patients with known HIV status 184 (82)
HIV-positive TB patients 1 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0 (0)
HIV-positive TB patients on antiretroviral therapy (ART) 1 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 1.9 (0.39–5.4) 100 (2.5–100)
MDR-TB cases among notified pulmonary
TB cases
3 (1–8) 0 (0–0)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 160 (108%) 1 161
Laboratory-confirmed MDR-TB cases 3 1 4
Patients started on MDR-TB treatment     0
Financing TB control 2013
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-23 Data: www.who.int/tb/data